批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2024/10/10 |
SUPPL-7(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2024/10/10 |
SUPPL-5(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2024/10/10 |
SUPPL-1(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2024/03/20 |
SUPPL-4(补充) |
Approval |
REMS |
|
|
|
2022/12/16 |
SUPPL-2(补充) |
Approval |
REMS |
|
|
|
2022/06/02 |
ORIG-1(原始申请) |
Approval |
|
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号 | 专利号 | 专利过期日 | 是否物质专利 | 是否产品专利 | 专利用途代码 | 撤销请求 | 提交日期 | 专利下载 | 备注 |
无 |
与本品治疗等效的药品
活性成分:BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE 剂型/给药途径:FILM;BUCCAL, SUBLINGUAL 规格:EQ 8MG BASE;EQ 2MG BASE 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
022410 |
002 |
NDA |
SUBOXONE |
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE |
FILM;BUCCAL, SUBLINGUAL |
EQ 8MG BASE;EQ 2MG BASE |
Prescription |
Yes |
No |
AB |
2010/08/30
|
INDIVIOR |
205299 |
002 |
ANDA |
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE |
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE |
FILM;BUCCAL, SUBLINGUAL |
EQ 8MG BASE;EQ 2MG BASE |
Prescription |
No |
No |
AB |
2018/06/14
|
DR REDDYS LABS SA |
207607 |
001 |
ANDA |
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE |
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE |
FILM;BUCCAL, SUBLINGUAL |
EQ 8MG BASE;EQ 2MG BASE |
Prescription |
No |
No |
AB |
2018/06/14
|
MYLAN TECHNOLOGIES |
205954 |
003 |
ANDA |
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE |
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE |
FILM;BUCCAL, SUBLINGUAL |
EQ 8MG BASE;EQ 2MG BASE |
Prescription |
No |
No |
AB |
2019/01/24
|
ALVOGEN |
212756 |
001 |
ANDA |
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE |
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE |
FILM;BUCCAL, SUBLINGUAL |
EQ 8MG BASE;EQ 2MG BASE |
Prescription |
No |
No |
AB |
2022/06/02
|
DIFGEN PHARMS |
活性成分:BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE 剂型/给药途径:FILM;BUCCAL, SUBLINGUAL 规格:EQ 12MG BASE;EQ 3MG BASE 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
022410 |
004 |
NDA |
SUBOXONE |
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE |
FILM;BUCCAL, SUBLINGUAL |
EQ 12MG BASE;EQ 3MG BASE |
Prescription |
Yes |
Yes |
AB |
2012/08/10
|
INDIVIOR |
205806 |
002 |
ANDA |
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE |
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE |
FILM;BUCCAL, SUBLINGUAL |
EQ 12MG BASE;EQ 3MG BASE |
Prescription |
No |
No |
AB |
2018/06/14
|
DR REDDYS LABS SA |
207607 |
002 |
ANDA |
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE |
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE |
FILM;BUCCAL, SUBLINGUAL |
EQ 12MG BASE;EQ 3MG BASE |
Prescription |
No |
No |
AB |
2018/06/14
|
MYLAN TECHNOLOGIES |
205954 |
004 |
ANDA |
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE |
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE |
FILM;BUCCAL, SUBLINGUAL |
EQ 12MG BASE;EQ 3MG BASE |
Prescription |
No |
No |
AB |
2019/01/24
|
ALVOGEN |
212756 |
002 |
ANDA |
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE |
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE |
FILM;BUCCAL, SUBLINGUAL |
EQ 12MG BASE;EQ 3MG BASE |
Prescription |
No |
No |
AB |
2022/06/02
|
DIFGEN PHARMS |